Momelotinib: Mechanism of action, clinical, and translational science
Clinical and Translational Science · 2024-08 · 17 (8)
DOI: 10.1111/cts.70018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 27.08.2024. Verfasst von Georgios Vlasakakis und 8 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Translational Research, Biomedical. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
Myelofibrosis is a chronic myeloproliferative disorder characterized by bone marrow fibrosis, splenomegaly, anemia, and constitutional symptoms, with a median survival of ≈6 years from diagnosis. While currently approved Janus kinase (JAK) inhibitors (ruxolitinib, fedratinib) improve splenomegaly and symptoms, most can exacerbate myelofibrosis‐related anemia, a negative prognostic factor for survival. Momelotinib is a novel JAK1/JAK2/activin A receptor type 1 (ACVR1) inhibitor approved in the US, European Union, and the UK and is the first JAK inhibitor indicated specifically for patients with myelofibrosis with anemia. Momelotinib not only addresses the splenomegaly and symptoms associated with myelofibrosis by suppressing the hyperactive JAK–STAT (signal transducer and activator of transcription) pathway but also improves anemia and reduces transfusion dependency through ACVR1 inhibition. The recommended dose of momelotinib is 200 mg orally once daily, which was established after review of safety, efficacy, pharmacokinetic, and pharmacodynamic data. Momelotinib is metabolized primarily by CYP3A4 and excreted as metabolites in feces and urine. Steady‐state maximum concentration is 479 ng/mL (CV%, 61%), with a mean AUC tau of 3288 ng.h/mL (CV%, 60%); its major metabolite, M21, is active (≈40% of pharmacological activity of parent), with a metabolite‐to‐parent AUC ratio of 1.4–2.1. This review describes momelotinib's mechanism of action, detailing how the JAK–STAT pathway is involved in myelofibrosis pathogenesis and ACVR1 inhibition decreases hepcidin, leading to improved erythropoiesis. Additionally, it summarizes the pivotal studies and data that informed the recommended dosage and risk/benefit assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GSK, Collegeville, Pennsylvania, USA.
- Certara Drug Development Solutions, Sheffield, UK.
ORCID-Profile: Georgios Vlasakakis, Michael T McCabe, Yu Liu Ho, Geraldine Ferron-Brady, Paul Martin, Darren Bentley, Catherine Ellis, Sandra A G Visser
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Vlasakakis, G., McCabe, M. T., Ho, Y. L., Ferron-Brady, G., Martin, P., Bentley, D., Ellis, C., Antonysamy, M., & Visser, S. A. G. (2024). Momelotinib: Mechanism of action, clinical, and translational science. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.70018
Vancouver
Vlasakakis G, McCabe MT, Ho YL, Ferron-Brady G, Martin P, Bentley D, et al. Momelotinib: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.70018
BibTeX
@article{Vlasakakis2024,
author = {Vlasakakis, Georgios and McCabe, Michael T and Ho, Yu Liu and Ferron-Brady, Geraldine and Martin, Paul and Bentley, Darren and Ellis, Catherine and Antonysamy, Mary and Visser, Sandra A G},
title = {Momelotinib: Mechanism of action, clinical, and translational science},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {8},
doi = {10.1111/cts.70018}
}
EUVIMED